Geron Corp. (GERN)

Q: What's priced into Geron Corp. (GERN) stock?

The evidence gives no direct valuation or market-expectations measure, so whether GERN is cheap or expensive versus peers is unclear. Loss-making results mean the valuation case depends on future product growth and progress in development, rather than established profits.

Q: What does the Geron Corp. (GERN) outlook hinge on?

The multi-year view hinges on continued RYTELO growth, expense control, and progress in the Phase 3 IMpactMF trial, for which the snapshot provides no specific milestone data yet. A guidance cut would be a meaningful negative, while stronger results and guidance from healthcare peers could support sector momentum.

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.12-0.88%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Geron Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	65.69M
EPS	—	-0.002
FY 2026 · Annual
Revenue	—	235.36M
Revenue (RYTELO)	$220M–$240M	—
EPS	—	-0.045
Operating expenses	$230M–$240M	—
FY 2027 · Annual
Revenue	—	341.04M
EPS	—	0.074

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Management stability and execution	A supporting condition in Geron Corp.'s published investment case. The stated target is stable leadership and execution progress.	Improving	further key executive departures or failed restructuring	Qualitative: Stable leadership, RYTELO revenue near high-end guidance Recent news highlights RYTELO revenue expansion and stable leadership, supporting the improving status without trip conditions. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Total operating expenses	Operating expenses are guided around $230 million, showing cost discipline.	Intact	operating expenses exceed $240 million in FY26	Operating margin: -21.74% FY2026-Q2; GAAP. Published target: >= $230 million and <= $240 million. Target and observation currencies differ. Source published Aug 5, 2026-21.739736 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 39343f0a-2773-45da-a749-92f82033ebbf. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
RYTELO net product revenue	Geron aims for RYTELO product sales near $230 million in 2026.	Intact	revenue falls below $220 million in FY26	Product revenue: $57.473M FY2026-Q2; reported segment. Published target: >= $220 million and <= $240 million. Target period is not explicitly aligned with this observation. Source published Aug 5, 202657,473,000 USD · source valueLast status assessment Oct 24, 2026 Measurement source Product · reported segment FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_segment_revenue. Reference: 2026-Q2. Source status: vendor observation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

$0.33B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$333,135,830	2 / 6
2026-07-25	Unavailable	$333,136,667	4 / 5
2026-07-26	Unavailable	$342,335,000	2 / 5
2026-07-27	Unavailable	$342,335,000	2 / 5
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	$342,335,000	2 / 5
2026-07-30	Unavailable	$342,335,000	2 / 5
2026-07-31	Unavailable	$342,335,000	2 / 5
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	$342,335,000	2 / 5
2026-08-03	Unavailable	$342,335,000	2 / 5
2026-08-04	Unavailable	$342,335,000	2 / 5
2026-08-05	Unavailable	$342,335,000	2 / 5
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	$342,375,000	2 / 5
2026-08-09	Unavailable	$342,375,000	2 / 5
2026-08-10	Unavailable	$342,375,000	2 / 5
2026-08-12	Unavailable	$341,962,200	1 / 5
2026-08-13	Unavailable	$341,962,200	1 / 5
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	3 / 4
2026-08-30	Unavailable	Unavailable	3 / 4
2026-08-31	Unavailable	Unavailable	3 / 4
2026-09-01	Unavailable	Unavailable	3 / 4
2026-09-02	Unavailable	Unavailable	3 / 4
2026-09-03	Unavailable	Unavailable	3 / 4
2026-09-04	Unavailable	Unavailable	3 / 4
2026-09-05	Unavailable	Unavailable	3 / 4
2026-09-06	Unavailable	Unavailable	3 / 4
2026-09-07	Unavailable	Unavailable	3 / 4
2026-09-08	Unavailable	Unavailable	3 / 4
2026-09-09	Unavailable	Unavailable	3 / 4
2026-09-10	Unavailable	Unavailable	3 / 4
2026-09-11	Unavailable	Unavailable	3 / 4
2026-09-12	Unavailable	Unavailable	3 / 4
2026-09-13	Unavailable	Unavailable	3 / 4
2026-09-14	Unavailable	Unavailable	3 / 4
2026-09-15	Unavailable	Unavailable	3 / 4
2026-09-16	Unavailable	Unavailable	3 / 4
2026-09-17	Unavailable	Unavailable	3 / 4
2026-09-18	Unavailable	Unavailable	3 / 4
2026-09-19	Unavailable	Unavailable	3 / 4
2026-09-20	Unavailable	Unavailable	3 / 4
2026-09-21	Unavailable	Unavailable	3 / 4
2026-09-22	Unavailable	Unavailable	3 / 4
2026-09-23	Unavailable	Unavailable	3 / 4
2026-09-24	Unavailable	Unavailable	3 / 4
2026-09-25	Unavailable	Unavailable	3 / 4
2026-09-26	Unavailable	Unavailable	3 / 4
2026-09-27	Unavailable	Unavailable	3 / 4
2026-09-28	Unavailable	Unavailable	3 / 4
2026-09-29	Unavailable	Unavailable	3 / 4
2026-09-30	Unavailable	Unavailable	3 / 4
2026-10-01	Unavailable	Unavailable	3 / 4
2026-10-02	Unavailable	Unavailable	3 / 4
2026-10-03	Unavailable	Unavailable	3 / 4
2026-10-04	Unavailable	Unavailable	3 / 4
2026-10-05	Unavailable	Unavailable	3 / 4
2026-10-06	Unavailable	Unavailable	3 / 4
2026-10-07	Unavailable	Unavailable	3 / 4
2026-10-08	Unavailable	Unavailable	3 / 4
2026-10-09	Unavailable	Unavailable	3 / 4
2026-10-10	Unavailable	Unavailable	3 / 4
2026-10-11	Unavailable	Unavailable	3 / 4
2026-10-12	Unavailable	Unavailable	3 / 4
2026-10-13	Unavailable	Unavailable	3 / 4
2026-10-14	Unavailable	Unavailable	3 / 4
2026-10-15	Unavailable	Unavailable	3 / 4
2026-10-16	Unavailable	Unavailable	3 / 4
2026-10-17	Unavailable	Unavailable	3 / 4
2026-10-18	Unavailable	Unavailable	3 / 4
2026-10-19	Unavailable	Unavailable	3 / 4
2026-10-20	Unavailable	Unavailable	3 / 4
2026-10-21	Unavailable	Unavailable	3 / 4
2026-10-22	Unavailable	Unavailable	3 / 4
2026-10-23	Unavailable	Unavailable	3 / 4
2026-10-24	Unavailable	Unavailable	3 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	1	1
2026-06-01	4	1	1
2026-07-01	4	1	1
2026-08-01	4	1	0
2026-09-01	4	1	0
2026-10-01	4	1	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Total operating expensesOperating margin: -21.74%
RYTELO net product revenueProduct revenue: $57.473M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-43.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Geron Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a clinical-stage biopharmaceutical company with a commercial product, so the thesis combines product growth with trial execution. The long-term thesis is intact, though the recent signal has shifted from mildly favorable to mixed and the risk level is elevated.

What's priced into Geron Corp.

The evidence gives no direct valuation or market-expectations measure, so whether GERN is cheap or expensive versus peers is unclear. Loss-making results mean the valuation case depends on future product growth and progress in development, rather than established profits.

What the fundamentals likely do

Near term, RYTELO revenue growth supports the business: first-half 2026 revenue rose 24% year over year, and management reiterated its full-year guidance. Expenses rose year over year, and the next results carry elevated miss risk; the last reported earnings were in line.

What Geron Corp. hinges on